Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland
- 1 June 2001
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 9 (6), 404-408
- https://doi.org/10.1038/sj.ejhg.5200655
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- Maternal age‐ and gestation‐specific risk for trisomy 21Ultrasound in Obstetrics & Gynecology, 1999
- First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta=hCG in combination with fetal nuchal translucency thicknessBJOG: An International Journal of Obstetrics and Gynaecology, 1998
- Screening of Maternal Serum for Fetal Down's Syndrome in the First TrimesterNew England Journal of Medicine, 1998
- First‐trimester screening for fetal aneuploidy: biochemistry and nuchal translucencyUltrasound in Obstetrics & Gynecology, 1997
- Increased Nuchal Translucency as a Marker for Fetal Chromosomal DefectsNew England Journal of Medicine, 1997
- Combining Ultrasound and Biochemistry in First-Trimester Screening for Down's syndromePrenatal Diagnosis, 1997
- First Trimester Aneuploidy Screening Using Nuchal Iranslucency, Free Beta Human Chorionic Gonadotrophin and Maternal AgeAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1996
- First‐trimester diagnosis of nuchal anomalies: significance and fetal outcomeUltrasound in Obstetrics & Gynecology, 1992
- Ultrasonographically detectable markers of fetal chromosomal abnormalitiesThe Lancet, 1992